LEADER 03539nam  22005534a 450 
001 9910877810603321
005 20200520144314.0
010   $a1-280-19728-5
010   $a9786610197286
010   $a0-470-79102-0
010   $a0-470-99471-1
010   $a1-4051-4097-6
035   $a(CKB)1000000000351278
035   $a(EBL)233111
035   $a(OCoLC)437147415
035   $a(SSID)ssj0000150751
035   $a(PQKBManifestationID)11162908
035   $a(PQKBTitleCode)TC0000150751
035   $a(PQKBWorkID)10281330
035   $a(PQKB)11450239
035   $a(MiAaPQ)EBC233111
035   $a(EXLCZ)991000000000351278
100   $a20040608d2004      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aEvaluating pharmaceuticals for health policy and reimbursement /$fedited by Nick Freemantle and Suzanne Hill
210   $aMalden, Mass. $cBMJ Books/Blackwell Pub.$d2004
215   $a1 online resource (280 p.)
300   $aDescription based upon print version of record.
311   $a0-7279-1784-6 
320   $aIncludes bibliographical references and index.
327   $aDevelopment of marketing authorisation procedures for pharmaceuticals / Alar Irs, Truus Janse de Hoog, Lembit Rago -- Interpreting clinical evidence / Nick Freemantle ... [et al.] -- International pharmaceutical policy: health creation or wealth creation? / Karen Bloor, Alan Maynard -- Development of fourth hurdle policies around the world / Rod S. Taylor ... [et al.] -- Economic modelling in drug reimbursement / Glenn Salkeld, Nick Freemantle, Bernie O'Brien -- Priority setting in health care: matching decision criteria with policy objectives / Gina Brinsmead, Alan Williams -- Tensions in licensing and reimbursement decisions: the case of riluzole for amyotrophic lateral sclerosis / Stirling Bryan ... [et al.] --
327   $aRelationships between stakeholders: managing the war of words / Suzanne Hill, Kees de Joncheere -- Medicine and the media: good information or misleading hype? / Ray Moynihan, Lisa M. Schwartz, Steven Woloshin -- How to promote quality use of cost-effective medicines / Hans Hogerzeil, Kathleen Holloway -- Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable / Andrew Mitchell -- Pricing of pharmaceuticals / David Newby, Andrew Creese, Alan Stevens -- Evaluating pharmaceuticals for health policy in low and middle income country settings / Andrew Creese ... [et al.].
330   $a"The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable"   So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders.   
606   $aPharmaceutical policy
615  0$aPharmaceutical policy.
676   $a362.17/82
701   $aFreemantle$b Nick$0983439
701   $aHill$b Suzanne$0877980
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910877810603321
996   $aEvaluating pharmaceuticals for health policy and reimbursement$92245004
997   $aUNINA